{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:36:13Z","timestamp":1734500173851,"version":"3.30.2"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,17]]},"DOI":"10.7759\/cureus.75889","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T17:50:23Z","timestamp":1734457823000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety of COVID-19 Vaccines in Patients With Multiple Sclerosis: A Cross-Sectional Study From a Tertiary Rehabilitation Center in Saudi Arabia"],"prefix":"10.7759","author":[{"given":"Sherif","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaz A","family":"Elkarim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuja'a A","family":"Al-Jaberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston A","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008, 372:1502-17. 10.1016\/S0140-6736(08)61620-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54852","article-title":"The safety profile of common COVID-19 vaccines in patients with multiple sclerosis","volume":"16","author":"Aladdin YS","year":"2024","unstructured":"Aladdin YS, Alqarni DA, Alamoudi SW, Alharbi AA, Fudhah WA, Alghamdi G, Attar A. The safety profile of common COVID-19 vaccines in patients with multiple sclerosis. Cureus. 2024, 16:e54852. 10.7759\/cureus.54852","journal-title":"Cureus"},{"key":"ref3","unstructured":"The World Health Organization. COVID-19 advice for the public. getting vaccinated. (2024). Accessed: September 19, 2024: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9040330","article-title":"COVID-19 vaccine hesitancy among young adults in Saudi Arabia: a cross-sectional web-based study","volume":"9","author":"Almaghaslah D","year":"2021","unstructured":"Almaghaslah D, Alsayari A, Kandasamy G, Vasudevan R. COVID-19 vaccine hesitancy among young adults in Saudi Arabia: a cross-sectional web-based study. Vaccines (Basel). 2021, 9:330. 10.3390\/vaccines9040330","journal-title":"Vaccines (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103225","article-title":"MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis","volume":"56","author":"Yamout BI","year":"2021","unstructured":"Yamout BI, Zakaria M, Inshasi J, et al.. MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Mult Scler Relat Disord. 2021, 56:103225. 10.1016\/j.msard.2021.103225","journal-title":"Mult Scler Relat Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001104","article-title":"COVID-19 vaccination reactogenicity in persons with multiple sclerosis","volume":"9","author":"Briggs FB","year":"2022","unstructured":"Briggs FB, Mateen FJ, Schmidt H, et al.. COVID-19 vaccination reactogenicity in persons with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022, 9:e1104. 10.1212\/NXI.0000000000001104","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102439","article-title":"Effects of MS disease-modifying therapies on responses to vaccinations: a review","volume":"45","author":"Ciotti JR","year":"2020","unstructured":"Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord. 2020, 45:102439. 10.1016\/j.msard.2020.102439","journal-title":"Mult Scler Relat Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117011","article-title":"Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide","volume":"416","author":"Bollo L","year":"2020","unstructured":"Bollo L, Guerra T, Bavaro DF, et al.. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. J Neurol Sci. 2020, 416:117011. 10.1016\/j.jns.2020.117011","journal-title":"J Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107374","article-title":"COVID-19 vaccination in people with multiple sclerosis, real-life experience","volume":"220","author":"Alroughani R","year":"2022","unstructured":"Alroughani R, Al-Hashel J, Abokalawa F, AlMojel M, Farouk Ahmed S. COVID-19 vaccination in people with multiple sclerosis, real-life experience. Clin Neurol Neurosurg. 2022, 220:107374. 10.1016\/j.clineuro.2022.107374","journal-title":"Clin Neurol Neurosurg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.73018","article-title":"Rehabilitation therapists have better job satisfaction than nurses in a tertiary rehabilitation healthcare setting: a cross-sectional study","volume":"16","author":"Bin Zarah AH","year":"2024","unstructured":"Bin Zarah AH, Al Mohareb M. Rehabilitation therapists have better job satisfaction than nurses in a tertiary rehabilitation healthcare setting: a cross-sectional study. Cureus. 2024, 16:e73018. 10.7759\/cureus.73018","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103954","article-title":"Fatigue in multiple sclerosis: a UK MS-register based study","volume":"64","author":"Moore H","year":"2022","unstructured":"Moore H, Nair KP, Baster K, Middleton R, Paling D, Sharrack B. Fatigue in multiple sclerosis: a UK MS-register based study. Mult Scler Relat Disord. 2022, 64:103954. 10.1016\/j.msard.2022.103954","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62541-x","article-title":"Vaccination status and self-reported side effects after SARS-CoV-2 vaccination in relation to psychological and clinical variables in patients with multiple sclerosis","volume":"14","author":"Burian K","year":"2024","unstructured":"Burian K, Heidler F, Frahm N, et al.. Vaccination status and self-reported side effects after SARS-CoV-2 vaccination in relation to psychological and clinical variables in patients with multiple sclerosis. Sci Rep. 2024, 14:12248. 10.1038\/s41598-024-62541-x","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221150881","article-title":"Safety of COVID-19 vaccines in multiple sclerosis: a systematic review and meta-analysis","volume":"29","author":"Stefanou MI","year":"2023","unstructured":"Stefanou MI, Palaiodimou L, Theodorou A, et al.. Safety of COVID-19 vaccines in multiple sclerosis: a systematic review and meta-analysis. Mult Scler. 2023, 29:585-94. 10.1177\/13524585221150881","journal-title":"Mult Scler"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti PM","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020, 396:467-78. 10.1016\/S0140-6736(20)31604-4","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al.. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020, 383:2603-15. 10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15028","article-title":"Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel","volume":"28","author":"Lotan I","year":"2021","unstructured":"Lotan I, Wilf-Yarkoni A, Friedman Y, Stiebel-Kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel. Eur J Neurol. 2021, 28:3742-8. 10.1111\/ene.15028","journal-title":"Eur J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002527","article-title":"Protecting people with multiple sclerosis through vaccination","volume":"20","author":"Reyes S","year":"2020","unstructured":"Reyes S, Ramsay M, Ladhani S, et al.. Protecting people with multiple sclerosis through vaccination. Pract Neurol. 2020, 20:435-45. 10.1136\/practneurol-2020-002527","journal-title":"Pract Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021","volume":"27","author":"Achiron A","year":"2021","unstructured":"Achiron A, Dolev M, Menascu S, et al.. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler. 2021, 27:864-70. 10.1177\/13524585211003476","journal-title":"Mult Scler"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8263-4","article-title":"Vaccines and multiple sclerosis: a systematic review","volume":"264","author":"Mailand MT","year":"2017","unstructured":"Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. J Neurol. 2017, 264:1035-50. 10.1007\/s00415-016-8263-4","journal-title":"J Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.721502","article-title":"Severe multiple sclerosis relapse after COVID-19 vaccination: a case report","volume":"12","author":"Maniscalco GT","year":"2021","unstructured":"Maniscalco GT, Manzo V, Di Battista ME, Salvatore S, Moreggia O, Scavone C, Capuano A. Severe multiple sclerosis relapse after COVID-19 vaccination: a case report. Front Neurol. 2021, 12:721502. 10.3389\/fneur.2021.721502","journal-title":"Front Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211012835","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron A","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S, et al.. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021, 14:17562864211012835. 10.1177\/17562864211012835","journal-title":"Ther Adv Neurol Disord"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211061543","article-title":"Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America","volume":"7","author":"Alonso R","year":"2021","unstructured":"Alonso R, Chertcoff A, Leguizam\u00f3n FD, et al.. Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. Mult Scler J Exp Transl Clin. 2021, 7:20552173211061543. 10.1177\/20552173211061543","journal-title":"Mult Scler J Exp Transl Clin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/327248-safety-of-covid-19-vaccines-in-patients-with-multiple-sclerosis-a-cross-sectional-study-from-a-tertiary-rehabilitation-center-in-saudi-arabia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T17:50:28Z","timestamp":1734457828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/327248-safety-of-covid-19-vaccines-in-patients-with-multiple-sclerosis-a-cross-sectional-study-from-a-tertiary-rehabilitation-center-in-saudi-arabia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.75889","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}